15605 results about "Dry powder" patented technology

A hemostatic composition for stopping or decreasing blood flow from an open wound or medical or surgical procedure. Compositions of the invention comprise a mixture of a cationic polymer and a cation exchange material. In one embodiment, the composition comprises a mixture: (1) a high molecular weight copolymer of diallyl dimethyl ammonium chloride (DADMAC) and acrylamide [DADMAC copolymer], and (2) the hydrogen form of a crosslinked, sulfonated polystyrene (hydrogen resin). In an exemplified embodiment, a composition of the invention comprises the mixture of DADMAC copolymer and hydrogen resin provided in a dry powdered form. The compositions of the invention may be applied directly to a wound or treatment site, or they may be incorporated into a wound dressing, such as a bandage. The seal formed at a wound or treatment site treated with the present invention is adhesive and exhibits considerable toughness.

In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful election of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein.

An inhaler for multiple dosed administration of a pharmacological dry powder consists externally of a housing (100,150) and of a protective cap (950) which can be removed from a special mouthpiece (900) fitted on the housing. Arranged on the inside there are a slide rail (200), a dosing slide (300), a shutter (400), a carriage (500), a funnel arrangement (600), a counter device (700), a valve shield (800) and a valve guide (850). Removal of the protective cap (950) initiates the dosing, with a dose received in the dosing cavity (302) being transported to the mouth-piece (900) by means of the dosing slide (300). Only upon application of a defined minimum intensity of inhalation is the shutter (400) moved by the suctioned valve shield (800), as a result of which the dose is released for inhalation. Completed with an electronic module and a controllable nozzle, all inhalation-relevant data can be recorded and the flow conditions regulated.

According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (% w) water, usually below about 5% w and preferably less than about 3% w; a particle size of about 1.0-5.0 mum mass median diameter (MMD), usually 1.0-4.0 mum MMD, and preferably 1.0-3.0 mum MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 mum mass median aerodynamic diameter (MMAD), usually 1.5-4.5 mum MMAD, and preferably 1.5-4.0 MMAD. Such composition are of pharmaceutical grade purity.

A process for preparing ultrafine powders of biological macromolecules comprises atomizing liquid solutions of the macromolecules, drying the droplets formed in the atomization step, and collecting the particles which result from drying. By properly controlling each of the atomization, drying, and collection steps, ultrafine dry powder compositions having characteristics particularly suitable for pulmonary delivery for therapeutic and other purposes may be prepared.

A dry powder composition comprising one or more potent pharmaceutically active substances and a carrier substance, all of which are in finely divided form, wherein the formulation has a poured bulk density of from 0.28 to 0.38 g / ml is useful in the treatment of respiratory disorders.

A new dry powder inhaler is developed as a pulmonary medicine delivery device for dispersing precise tiny dosages (10 μg-50 mg) of pure carrier-free ultra-fine powdered medicament (<5 μm aerodynamics particle size) into a patient's lung. The powder is drawn from the blister cell and dispersed through an outlet tube assisted by two air streams. The first air stream goes through a the blister cell from its upstream side, to significantly fluidize the medicament in the dose to flow upward. The second one extracts the fluidized powder from downstream of the blister cell for further deagglomeration and dispersion of the medicament powder by shear force. The rotating multi-dose blister can hold up to 60 doses, which are pre-metered with pure ultra-fine powdered medicament. So that it has higher drug loading capability in small volumes, compared to most current dry powder inhalers, which usually use some excipient. The inhaler efficiently disperse the aerosolized medicament in the air stream to the deep interior of patient's lung. The fine particle fraction (<4.7 μm) is reported to reach as high as 80% using this inhaler.

Methods are provided for making a dry powder blend pharmaceutical formulation, comprising the steps of: (a) providing microparticles which comprise a pharmaceutical agent; (b) blending the microparticles with at least one excipient in the form of particles to form a powder blend; and (c) jet milling the powder blend to form a dry powder blend pharmaceutical formulation having improved dispersibility, suspendability, or wettability as compared to the microparticles of step (a) or the powder blend of step (b). The method can further include dispersing the dry powder blend pharmaceutical formulation in a liquid pharmaceutically acceptable vehicle to make an formulation suitable for injection. Alternatively, the method can further include processing the dry powder blend pharmaceutical formulation into a solid oral dosage form. In one embodiment, the microparticles of step (a) are formed by a solvent precipitation or crystallization process.

The present invention includes dry powder inhalers and associated multi-dose dry powder packages for holding inhalant formulated dry powder substances and associated fabrication and dispensing methods. The multi-dose package can include a platform body comprising at least one thin piezoelectric polymer material layer defining at least a portion of a plurality of spatially separated discrete elongate dry powder channels having an associated length, width and height; and a metallic material attached to selected portions of the piezoelectric polymer material including each of the regions corresponding to the elongate dry powder channels to, in operation, define active energy releasing vibratory channels. In operation, the elongate channels can be selectively individually activated to vibrate upon exposure to an electrical input.The dry powder inhaler includes an elongate body having opposing first and second outer primary surfaces with a cavity therebetween and having opposing top and bottom end portions and a multi-dose sealed blister package holding a plurality of discrete meted doses of a dry powder inhalable product located in the cavity of the elongate body. The inhaler also includes an inhalation port formed in the bottom end portion of the elongate body, the inhalation port configured to be in fluid communication with at least one of the discrete meted doses during use and a cover member that is pivotably attached to the elongate body so that it remains attached to the body during normal operational periods of use and moves to a first closed position to overlie the inhalation port at the bottom end portion of the body during periods of non-use and moves to a second open position away from the inhalation port during periods of use to allow a user to access the inhalation port.

This invention relates to dispersible antibody compositions and methods for preparing and using these compositions. In particular, the present invention relates to dry powder dispersible antibody compositions wherein antibody conformation is preserved. The compositions have good powder dispersibility and other desirable characteristics for pulmonary delivery of therapeutic antibodies.

The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and / or lower airway passages and / or lungs, e.g., allergic rhinitis and asthma is disclosed.

Dry powder pharmaceutical formulations for pulmonary or nasal administration are made to provide an improved respired dose. These formulations may be blends of milled blends and may include a phospholipid, alone or in combination with other excipient materials. In one case, the process includes the steps of (a) providing particles which comprise a pharmaceutical agent, (b) blending the particles with particles of at least one first excipient to form a first powder blend; (c) milling the first powder blend to form a milled blend which comprises microparticles or nanoparticles of the pharmaceutical agent; and (d) blending the milled blend with particles of a second excipient to form a blended dry powder blend pharmaceutical formulation suitable for pulmonary or nasal administration.

A dry powdered flowable cement composition contains calcium carbonate and a partially decarbonated magnesium carbonate. A slurry of the composition will set hard with various organic fillers including waste products and toxic waste. The composition can be slurried with contaminated water such as sea water, mineral laden ground water and muddy water. A high percentage of filler can be added while still having an acceptable set.

An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.

Drug formulations for systemic drug delivery with improved stability and rapid onset of action are described herein. The formulations may be administered via buccal administration, sublingual administration, pulmonary delivery, nasal administration, subcutaneous administration, rectal administration, vaginal administration, or ocular administration. In the preferred embodiments, the formulations are administered sublingually or via subcutaneous injection. The formulations contain an active agent and one or more excipients, selected to increase the rate of dissolution. In the preferred embodiment, the drug is insulin, and the excipients include a metal chelator such as EDTA and an acid such as citric acid. Following administration, these formulations are rapidly absorbed by the oral mucosa when administered sublingually and are rapidly absorbed into the blood stream when administered by subcutaneous injection. In one embodiment, the composition is in the form of a dry powder. In another embodiment, the composition is in the form of a film, wafer, lozenge, capsule, or tablet. In a third embodiment, a dry powdered insulin is mixed with a diluent containing a pharmaceutically acceptable carrier, such as water or saline, a metal chelator such as EDTA and an acid such as citric acid. Devices for storing and mixing these formulations are also described.

A system and method for a patch-like, self-contained multi-component substance infusion device which provides one or more substantially hidden patient needles which can be placed in fluid communication with a fluid reservoir assembly that includes a rigid bladder portion used in conjunction with a non-distensible bladder film, such as a metallized film. The device can be attached to a skin surface via an adhesive contact and a pressurization system provides a pressure to the contents of a fluid reservoir assembly. Improvements to dry powdered formulations for reconstitution for preferred use in the device are also disclosed.

Drug formulations for systemic drug delivery with improved stability and rapid onset of action are described herein. The formulations may be administered via buccal administration, sublingual administration, pulmonary delivery, nasal administration, subcutaneous administration, rectal administration, vaginal administration, or ocular administration. In the preferred embodiments, the formulations are administered sublingually or via subcutaneous injection. The formulations contain an active agent and one or more excipients, selected to increase the rate of dissolution. In the preferred embodiment, the drug is insulin, and the excipients include a metal chelator such as EDTA and an acid such as citric acid. Following administration, these formulations are rapidly absorbed by the oral mucosa when administered sublingually and are rapidly absorbed into the blood stream when administered by subcutaneous injection. In one embodiment, the composition is in the form of a dry powder. In another embodiment, the composition is in the form of a film, wafer, lozenge, capsule, or tablet. In a third embodiment, a dry powdered insulin is mixed with a diluent containing a pharmaceutically acceptable carrier, such as water or saline, a metal chelator such as EDTA and an acid such as citric acid. Devices for storing and mixing these formulations are also described.

A dry powder formulation for mucosal, intranasal, inhalation or pulmonary delivery which may include one or more siRNAs or dicer-active precursors thereof targeted to a transcript involved in infection by, or replication or production of an influenza virus.

The invention relates to a multifunctional blending and liquid supplying vehicle, which comprises a chassis, wherein an operation platform, a hydraulic oil tank, a dry powder feeder, an operation box for an electrical control system, a lorry-mounted crane and a liquid adding tank are fixedly arranged above the main beam of the chassis, wherein a centrifugal pump, an exhaust manifold and a suction manifold are arranged on each of two sides of the middle part of the main beam of the chassis, the exhaust manifold is communicated with the water outlet of the centrifugal pump, and the suction manifold is communicated with the water inlet of the centrifugal pump; the liquid adding pump is fixedly arranged on the side wall of the liquid adding tank, the water inlet of the liquid adding pump is communicated with the liquid adding tank, and the water outlet of the liquid adding tank is communicated with the exhaust manifold; a discharge opening in the lower end of the dry powder feeder is communicated with the exhaust manifold; the engine of the chassis is connected with a hydraulic pump, and the hydraulic pump is connected with the centrifugal pump, the lorry-mounted crane, the liquid adding tank and the liquid adding pump through a hydraulic multiway valve; the electrical control system is connected with the engine of the chassis, the hydraulic pump and the hydraulic multiway valve. The multifunctional blending and liquid supplying vehicle provided by the invention is low in cost, high in working efficiency, and can achieve various oil field operation functions.

The invention relates to a fracturing fluid and sand mixing semitrailer, and belongs to the field of fracturing devices for oil field work. The fracturing fluid and sand mixing semitrailer comprises a semitrailer body, a hydraulic system and an electrical control system. The hydraulic system comprises a hydraulic oil tank, at least one hydraulic pump and a hydraulic multi-way valve. An engine, the hydraulic system, the electrical control system, a lifting control chamber, a spiral conveyor, a clean water suction centrifugal pump, a fracturing fluid suction centrifugal pump, a stirring machine, a discharge centrifugal pump, a liquid adding pump, a dry powder adding device and a concentrated guanidine gum adding pump are integrated on the semitrailer body. The work steps of conducting glue solution mixing after fracturing liquid mixing is conducted and discharging the glue solution to a downward fracturing device can be conducted by operating the electrical control system to drive the hydraulic pump through an operator, and therefore work steps of oil field work are highly integrated, matched devices are reduced, workloads of working staff are reduced, and construction quality is ensured.

Powder type culture medium is from plenty of element kinds , trace element and iron salt and vitamin kind of composition, after processing manufacture the original powder that makes powder culture medium. The various components of the medium and the final product were dry powder. The preparation Method: First, concentrate all plenty of elements to collect reserve; Mix trace element and vitamin kind totally to wrap to attach , and then mix the thin medicine and plenty of elements of trace element totally, under the role with centrifugal high speed, making it even scatter and wrap up to glue to unite. So, make the original powder of powder culture medium for manufacture. This medium-dry powder manufacturing easier, does not require the use of complex machines and equipment, and low-cost easy to promote. The product is of high quality in existing product. It can be used in plant breeding, tissue culture and molecular biology research, and can be used for various commercial purposes.

A method to produce a pale and / or plain coloured wear resistant surface layer by using a dry powder layer comprising a mix of refined fibres binder, pigment and wear resistant particles.

This invention relates to a an orally disintegrating tablet obtainable by direct compression of a dry powdered mixture, said mixture comprising up to 15% by weight of calcium silicate, at least 50% of a diluent, a disintegrant agent and an active ingredient. It also relates to a process for preparing the tablets by homogeneous blending the specific excipients in powder form and subsequent direct compression of the mixture. Said tablets disintegrate quickly in the cavity of the mouth, in particular in less than 15 seconds.

In order to provide a spray dry method capable of producing a dry powder retaining the savor and flavor of a raw material and having solubility without any thermal deterioration, at a mass scale, a method for producing a dry powder keeping savor and flavor from a hydrous liquid material containing a savory and flavorful component and, preferably, a hygroscopic component by spray drying is disclosed, the method including spray drying the hydrous liquid material at the microfine liquid droplet state in gas atmosphere at the outlet temperature of a spray dryer at 20 to 90° C. and the outlet relative humidity of 1% RH to 40% RH, to prepare a dry powder of a mean particle size of 0.1 μm to 15 μm.